Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
NTLA Stock Chart & Stats
$9.52
-$0.56(-4.53%)
At close: 4:00 PM EST
$9.52
-$0.56(-4.53%)
Day’s Range― - ―
52-Week Range$5.90 - $28.25
Previous CloseN/A
Volume723.92K
Average Volume (3M)9.80M
Market Cap
$1.10B
Enterprise ValueN/A
Total Cash (Recent Filing)$511.04M
Total Debt (Recent Filing)$97.97M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Feb 19, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding115,829,926
10 Day Avg. Volume16,909,512
30 Day Avg. Volume9,795,825
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)1.32
Price to Sales (P/S)19.91
P/FCF Ratio-3.25
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$20.78Price Target Upside118.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessEfficacy data for nex-z has looked impressive, with durable reductions in TTR and functional benefits noted in the phase 1 trial.
Financial ValuationUsing an 11% discount rate and 3% terminal growth rate, our discounted cash flow (DCF)-based analysis has resulted in an estimated EV of ~$2B.
Market PotentialATTR-CM diagnosis has surged ~7X between 2016 and 2025 at Dr. Garcia's center, pointing to a growing addressable population.
Bears Say
Regulatory ChallengesThe FDA placed a formal clinical hold on the Phase III ATTR studies following safety concerns, causing a pause in enrollment.
Safety ConcernsThe patient who experienced the grade 4 liver safety event passed away, complicating the path to market.
Stock PerformanceIntellia shares are trading down over 20% aftermarket in response to news the ATTR-CM patient dosed with nex-z who was hospitalized with abdominal pain and triggered Hy’s law has died.
Intellia Therapeutics News
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $5.90 and its highest was $28.25 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.10B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 101 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.92 earnings per share for the quarter, beating the consensus estimate of -$1.005 by $0.085.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -0.98.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 115,829,926 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$0.92 in its last earnings report, beating expectations of -$1.005. Following the earnings report the stock price went down -22.727%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
Intellia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.78 (118.28% Upside)
$20.78 (118.28% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $969.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.50%
12-Months-Change
Fundamentals
Return on Equity
-52.11%
Trailing 12-Months
Asset Growth
-21.14%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. (NTLA) is a biotechnology company focused on developing transformative therapies using its proprietary CRISPR/Cas9 gene-editing technology. The company operates in the healthcare sector, primarily in the field of genetic medicine, targeting a range of diseases including genetic disorders, cancers, and other serious conditions. Intellia's core products and services revolve around its innovative gene-editing platform, which aims to provide one-time curative treatments by directly addressing the root causes of diseases at the genetic level.
NTLA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call presented a mix of progress and challenges. While significant advancements were made in the lonvo-z program and financial stability was maintained, the clinical hold on nex-z trials due to patient safety concerns significantly impacted the company's outlook. The sentiment is largely influenced by the serious nature of the clinical hold and patient safety issues.View all NTLA earnings summariesNTLA Revenue Breakdown
100.00% Collaboration revenue
NTLA Stock 12 Month Forecast
Average Price Target
$20.78
▲(118.28% Upside)
Technical Analysis
Xencor
―
Rocket Pharmaceuticals
―
Arvinas Holding Company
―
Vir Biotechnology
―
Nurix Therapeutics
―
Ownership Overview
1.85% Insiders
18.04% Mutual Funds
0.03% Other Institutional Investors
52.21% Public Companies and Individual Investors